Dimensional Fund Advisors LP decreased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 0.5% during the 2nd quarter, Holdings Channel reports. The firm owned 221,784 shares of the biotechnology company’s stock after selling 1,152 shares during the period. Dimensional Fund Advisors LP’s holdings in BioMarin Pharmaceutical were worth $20,885,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently bought and sold shares of BMRN. Nissay Asset Management Corp Japan ADV boosted its stake in shares of BioMarin Pharmaceutical by 4.8% in the second quarter. Nissay Asset Management Corp Japan ADV now owns 12,078 shares of the biotechnology company’s stock valued at $1,138,000 after buying an additional 556 shares during the period. Scout Investments Inc. boosted its stake in shares of BioMarin Pharmaceutical by 125.6% in the second quarter. Scout Investments Inc. now owns 214,099 shares of the biotechnology company’s stock valued at $20,168,000 after buying an additional 119,185 shares during the period. Gideon Capital Advisors Inc. bought a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $411,000. Canada Pension Plan Investment Board boosted its stake in shares of BioMarin Pharmaceutical by 68.4% in the second quarter. Canada Pension Plan Investment Board now owns 427,999 shares of the biotechnology company’s stock valued at $40,318,000 after buying an additional 173,850 shares during the period. Finally, Comerica Bank boosted its stake in shares of BioMarin Pharmaceutical by 35.3% in the second quarter. Comerica Bank now owns 9,531 shares of the biotechnology company’s stock valued at $991,000 after buying an additional 2,489 shares during the period.
In other news, EVP Jeffrey Robert Ajer sold 1,000 shares of the stock in a transaction on Wednesday, October 3rd. The stock was sold at an average price of $98.98, for a total value of $98,980.00. Following the completion of the transaction, the executive vice president now directly owns 49,135 shares in the company, valued at approximately $4,863,382.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jean Jacques Bienaime sold 1,500 shares of the stock in a transaction on Monday, July 23rd. The shares were sold at an average price of $101.69, for a total value of $152,535.00. Following the completion of the transaction, the chief executive officer now owns 286,790 shares of the company’s stock, valued at $29,163,675.10. The disclosure for this sale can be found here. Insiders have sold 75,023 shares of company stock valued at $7,497,878 over the last 90 days. Corporate insiders own 1.90% of the company’s stock.
Several brokerages recently issued reports on BMRN. BidaskClub upgraded BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, June 20th. ValuEngine upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Wednesday, October 3rd. Finally, Stifel Nicolaus boosted their price target on BioMarin Pharmaceutical from $102.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, August 3rd. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $116.12.
NASDAQ BMRN opened at $99.51 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.83 and a quick ratio of 2.24. BioMarin Pharmaceutical Inc. has a fifty-two week low of $75.81 and a fifty-two week high of $106.20. The firm has a market cap of $17.22 billion, a price-to-earnings ratio of -147.33 and a beta of 1.61.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03). BioMarin Pharmaceutical had a negative return on equity of 3.00% and a negative net margin of 8.68%. The business had revenue of $372.80 million for the quarter, compared to the consensus estimate of $359.25 million. During the same quarter in the previous year, the company earned ($0.21) earnings per share. The firm’s revenue for the quarter was up 17.4% on a year-over-year basis. As a group, analysts predict that BioMarin Pharmaceutical Inc. will post -0.24 EPS for the current fiscal year.
BioMarin Pharmaceutical Profile
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Featured Article: What is the S&P 500 Index?
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.